TP53 and metastatic neoplasm: We found that absence of TG2 in the TME did not prolong survival in the less metastatic model (KPCA.B) but did prolong survival in the highly metastatic model, ID8 Trp53-/- Brca1-/-, as was evident by the Tgm2 knockout mice having significantly less metastatic disease at 6 weeks after cell injection.